{
    "organizations": [],
    "uuid": "d52b216a3e9220a3dc37922d3c22dd8dd0094747",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-sanofi-announes-some-positive-phas/brief-sanofi-announes-some-positive-phase-3-trials-for-dupixent-idUSFWN1SM1ID",
    "ord_in_thread": 0,
    "title": "BRIEF-Sanofi announes some positive Phase 3 trials for Dupixent® (dupilumab)",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 16 (Reuters) - Sanofi:\n* Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis\n* U.S. regulatory submission for patients ages 12-17 planned for third quarter 2018\n* A pivotal Phase 3 trial evaluating Dupixent (®)(dupilumab) to treat moderate-to-severe atopic dermatitis in adolescents (ages 12-17) met its primary and key secondary endpoints\n* In the trial, treatment with Dupixent as monotherapy significantly improved measures of overall disease severity, skin clearing, itching, and certain health-related quality of life measures\n* Dupixent is the first and only biologic to show positive results in this patient population, adds Sanofi\n ",
    "published": "2018-05-16T13:10:00.000+03:00",
    "crawled": "2018-05-17T14:22:21.008+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "sanofi",
        "dupilumab",
        "showed",
        "positive",
        "phase",
        "result",
        "adolescent",
        "inadequately",
        "controlled",
        "atopic",
        "dermatitis",
        "regulatory",
        "submission",
        "patient",
        "age",
        "planned",
        "third",
        "quarter",
        "pivotal",
        "phase",
        "trial",
        "evaluating",
        "dupixent",
        "dupilumab",
        "treat",
        "atopic",
        "dermatitis",
        "adolescent",
        "age",
        "met",
        "primary",
        "key",
        "secondary",
        "endpoint",
        "trial",
        "treatment",
        "dupixent",
        "monotherapy",
        "significantly",
        "improved",
        "measure",
        "overall",
        "disease",
        "severity",
        "skin",
        "clearing",
        "itching",
        "certain",
        "quality",
        "life",
        "measure",
        "dupixent",
        "first",
        "biologic",
        "show",
        "positive",
        "result",
        "patient",
        "population",
        "add",
        "sanofi"
    ]
}